The antibody-drug conjugates market is fast evolving and is expected to grow significantly during the forecast period. The effectiveness of...
BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space,...
Central, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Central, Hong Kong - Maple Tree Counselling is committed to providing compassionate, evidence-based...
Funding will accelerate Together AI's leadership as the preferred AI Cloud for building modern AI applications with open source models,...
STOCKHOLM, Feb. 21, 2025 /PRNewswire/ -- Autoliv, Inc. (NYSE: ALV) (SSE: ALIV.sdb), the worldwide leader in automotive safety systems, has...
Currently More Than 400 Clinical Trials Studies Are Active In Saudi Arabia Says Kuick Research In New Research ReportDelhi, Feb....
NEW YORK, Feb. 21, 2025 /PRNewswire/ -- In a recent announcement, Bestqool is upgrading both the Pro100 and Pro200 to the...
SHENZHEN, China, Feb. 21, 2025 /PRNewswire/ -- INMOTION Technologies Co., Ltd., a global leader in intelligent personal mobility, has officially...
Samueli Transformed How Society Communicates, Connects, and Does Business Through His Pioneering Research and Commercialization of Broadband Communication and Networking Technologies...
YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 First-in-class...
